Some misleading narratives about Bourla’s leadership that have been put forward have been distinctly unfair,' write Jeff Sonnenfeld and Steven Tian.

Pfizer’s situation with activist investor Starboard Value is already getting messy. | After initially supporting a meeting with activist investor Starboard Value, Pfizer's former CEO and CFO publicly changed their tune after being threatened with litigation by Pfizer,

Pfizer chief executive Albert Bourla plans to meet Starboard Value, said people familiar with the matter, as the activist investor’s $1bn stake in the pharmaceutical group puts pressure on its board to revive its share price.